Safety and immunogenicity of two freeze-dried Vero cell rabies vaccines for human use in post-exposure prophylaxis

Vaccine

Volumn 29, Issue 15, 2011, Pages 2679-2681

  Wang, Ling yun ^a   Sun, Mei ping ^a   Zhang, Xue chun ^a   Suo, Luo dan ^a   Xu, Ruo hui ^b   Zou, Yan jie ^c   Zuo, Li bo ^d   Qi, Hua ^e  

^a CHINESE CENTER FOR DISEASE CONTROL AND PREVENTION   (China)

^b Haidian District Center for Diseases Prevention and Control   (China)

^c Institute for Infectious Diseases   (China)

^d Beijing Haidian Hospital   (China)

^e The Sixth Hospital of Beijing   (China)

Author keywords

Adverse reaction; Freeze dried Vero cell rabies vaccine for human use; Immunogenicity

Indexed keywords

NEUTRALIZING ANTIBODY; RABIES VACCINE; SPEEDA; UNCLASSIFIED DRUG; VEROVARB;

ADOLESCENT; ADULT; AGED; ANTIBODY BLOOD LEVEL; ANTIBODY TITER; ARTICLE; CHILD; CHINA; DRUG SAFETY; EDEMA; FEMALE; FEVER; FREEZE DRYING; HUMAN; HUMAN EXPERIMENT; IMMUNOGENICITY; INJECTION SITE INDURATION; INJECTION SITE SWELLING; MALE; NORMAL HUMAN; PRIORITY JOURNAL; RASH; RHINOSCLEROMA; SEROCONVERSION; VACCINATION; VERO CELL;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANIMALS; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; BIOTECHNOLOGY; CELL CULTURE TECHNIQUES; CERCOPITHECUS AETHIOPS; CHILD; CHILD, PRESCHOOL; CHINA; FEMALE; FREEZE DRYING; HUMANS; MALE; MIDDLE AGED; POST-EXPOSURE PROPHYLAXIS; RABIES VACCINES; TECHNOLOGY, PHARMACEUTICAL; VACCINATION; VERO CELLS; YOUNG ADULT;

EID: 79952242848     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2011.01.053     Document Type: Article

References (12)

1. Dong G.M. Rabies prevention and control, safety of vaccines and anti-serum. Chin J Prev Med 2006, 7(August (4)):362-365.
2. Stanley A.P., Walter A.O., Paul A.O. Vaccines 2008, Saunders, Imprint, p. 75. 5th ed.
3. Meslin F.X., Kaplan M.M., Koprowski H. Laboratory techniques in rabies 1996, WHO, Geneva, p. 7. 4th ed.
4. Fisbein D.B., Yenne K.M., Dreesen D.W., Teplis C.F., Mehta N., Briggs D.J. Risk factors for systemic hypersensitivity reactions after booster vaccinations with human diploid cells rabies vaccine: a nation-wide prospective study. Vaccine Nov 1993, 11(14):1390-1394.
5. Suntharasamai P., Chaiprasithikul P., Wasi C., Supanaranond W., Auewarakul P., Chanthavanich P., et al. A simplified and economical intradermal regimen of purified chick embryo cell rabies vaccine for postexposure prophylaxis. Vaccine May 1994, 12(6):508-512.
6. WHO expert consultation on rabies: first report. WHO technical report series 2004, vol. 931. WHO, Geneva.
7. Smith J.A., Yanger P.A., Baer G.M. Rapid fluorescent focus inhibition test for determining rabies virus-neutralizing antibody. Laboratory techniques in rabies 1996, 181-192. WHO, Geneva. F.-X. Meslin, M.M. Kaplan, H. Koprowski (Eds.).
8. Weekly epidemiological record, No. 49/50 2007, vol. 82. WHO, Geneva, p. 425-36.
9. Wilde H., Tipkong P., Khawplod P. Economic issues in post-exposure rabies treatment. J Travel Med 1999, 6(December (4)):238-242.
10. Costa W.A., Cunha R.S., Bolzan V.L., et al. Immunogenicity and safety of a new Vero cell rabies vaccine produced using serum-free medium. Vaccine 2007, 25(23 November (48)):8140-8145.
11. Wilde H., Tipkong P., Khawplod P. Economic issues in post-exposure rabies treatment. J Travel Med Dec 1999, 6(4):238-242.
12. Wang L.Y., Sun M.P., Zhang X.C., Xu R.H., ZOU Y.J., Zuo Q.B., et al. Vaccination reactions and immunogenicity of Chinese-made freeze-dried human-use rabies vaccine (Vero cell). Chin J Biol 2008, 21(December (12)):1115-1117.